Compare STC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STC | ZYME |
|---|---|---|
| Founded | 1893 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | N/A | 2017 |
| Metric | STC | ZYME |
|---|---|---|
| Price | $71.90 | $26.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $81.50 | $30.67 |
| AVG Volume (30 Days) | 260.5K | ★ 740.0K |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | ★ 69.60 | N/A |
| EPS | ★ 3.60 | N/A |
| Revenue | ★ $2,796,513,000.00 | $134,481,000.00 |
| Revenue This Year | $17.67 | $63.57 |
| Revenue Next Year | $10.14 | $89.45 |
| P/E Ratio | $19.95 | ★ N/A |
| Revenue Growth | 16.09 | ★ 116.21 |
| 52 Week Low | $56.39 | $9.03 |
| 52 Week High | $78.61 | $28.49 |
| Indicator | STC | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 45.24 | 61.80 |
| Support Level | $70.90 | $25.94 |
| Resistance Level | $73.66 | $27.94 |
| Average True Range (ATR) | 2.37 | 1.08 |
| MACD | -0.42 | -0.15 |
| Stochastic Oscillator | 23.28 | 65.71 |
Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments; Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.